Sugi Predict

Sugi Predict / Compounds / SCHEMBL6175041

SCHEMBL6175041

SCHEMBL6175041

O=C(O)c1cccc2[nH]c(=O)ccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PBRM1 Q86U86 2/20 0.54
▸ PARP1 P09874 1/20 0.50
▸ NR4A1 P22736 1/20 0.46
▸ NR4A2 P43354 1/20 0.46
▸ NR4A3 Q92570 1/20 0.46
▸ KDM4E B2RXH2 8/20 0.44
▸ NAPRT Q6XQN6 1/20 0.44
▸ TDP1 Q9NUW8 2/20 0.43
▸ PTPN1 P18031 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.43
▸ GAA P10253 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PDE3B Q13370 2/20 0.42
▸ PDE3A Q14432 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA3 P07451 1/20 0.42
▸ CA4 P22748 1/20 0.42
▸ CA6 P23280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30020580 1.00 PBRM1 (0.54) PBRM1PARP1NR4A1NR4A2NR4A3
SCHEMBL29593215 0.84 PDE3B (0.53) PBRM1KDM4EALDH1A1PDE3BPDE3A
SCHEMBL28721982 0.84 PDE3B (0.53) PBRM1KDM4EALDH1A1PDE3BPDE3A
SCHEMBL30380476 0.84 ALDH1A1 (0.47) PBRM1PARP1KDM4EALDH1A1GAA
SCHEMBL30706250 0.82 KDM4E (0.43) PBRM1PARP1KDM4EALDH1A1GAA
Naphthoic Acid SCHEMBL27643090 0.80 NR4A1 (0.64) PBRM1PARP1NR4A1NR4A2NR4A3
SCHEMBL28724402 0.80 PTPN1 (0.51) PBRM1KDM4EPTPN1ALDH1A1L3MBTL1
SCHEMBL1133930 0.80 NR4A2 (0.51) NR4A2KDM4EPTPN1ALDH1A1GAA
SCHEMBL29593165 0.80 PTPN1 (0.51) PBRM1KDM4EPTPN1ALDH1A1L3MBTL1
SCHEMBL8729784 0.78 KDM4E (0.63) KDM4ETDP1ALDH1A1GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246060-A1 Method Of Manufacture And Scale-Up Of The Metal-Organic Framework Cu(Qc)2 ExxonMobil Technology and Engineering Company 2024-07-25 — — US claimed
EP-4340989-A1 METHOD OF MANUFACTURE AND SCALE-UP OF THE METAL-ORGANIC FRAMEWORK CU(QC)2 ExxonMobil Technology and Engineering Company (US) 2024-03-27 — — EP claimed
CN-117377528-A Preparation method and large-scale production of metal-organic framework Cu (Qc) 2 埃克森美孚技术与工程公司 2024-01-09 — — CN claimed
WO-2022246150-A1 METHOD OF MANUFACTURE AND SCALE-UP OF THE METAL-ORGANIC FRAMEWORK CU(QC)2 ExxonMobil Technology and Engineering Company (US) 2022-11-24 — — WO claimed
EP-3911640-B1 PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE ASTRAZENECA AB (SE) 2026-05-13 — — EP disclosed
US-12584120-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-03-24 — — US disclosed
US-12552807-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-02-17 — — US disclosed
EP-4470609-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2024-12-04 — — EP disclosed
EP-3911648-B1 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-10-23 — — EP disclosed
US-20240246060-A1 Method Of Manufacture And Scale-Up Of The Metal-Organic Framework Cu(Qc)2 ExxonMobil Technology and Engineering Company 2024-07-25 — — US disclosed
EP-4340989-A1 METHOD OF MANUFACTURE AND SCALE-UP OF THE METAL-ORGANIC FRAMEWORK CU(QC)2 ExxonMobil Technology and Engineering Company (US) 2024-03-27 — — EP disclosed
CN-117377528-A Preparation method and large-scale production of metal-organic framework Cu (Qc) 2 埃克森美孚技术与工程公司 2024-01-09 — — CN disclosed
EP-1392280-A2 ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF Abbott GmbH & Co. KG (DE) 2004-03-03 — — EP disclosed
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY 2003-05-22 — — US disclosed
WO-2002089749-A2 ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF ABBOTT GMBH & CO.KG (DE) 2002-11-14 — — WO disclosed
US-RE34722-E Antiulcer agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-09-06 — — US disclosed
US-4578381-A ANTIULCER AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-03-25 — — US disclosed
US-4487772-A CARDIOTONIC AGENTS OTSUKA PHARMACEUTICAL CO. LTD. (JP) 1984-12-11 — — US disclosed
US-4468402-A Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-08-28 — — US disclosed
US-4454130-A CARDIOTONIC, HYPOTENSIVE AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-06-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof CASP1, IRAK1, STS PBRM1 2877/4885PARP1 2801/4885NR4A1 2818/4885
US-12552807-B2 PCSK9 inhibitors and methods of use thereof PCSK9, PCSK7, PCSK6 PBRM1 4111/4885PARP1 1349/4885NR4A1 1899/4885
US-12584120-B2 PCSK9 inhibitors and methods of use thereof PCSK9, LDLR, PCSK7 PBRM1 4756/4885PARP1 4664/4885NR4A1 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.